Against the wild-type strain of the virus, the two-dose vaccine posted 96.4% efficacy. Notably, the vaccine was also 100% effective in preventing severe disease, which included symptoms like tachypnea, high resting heart rate, required ventilation, hospitalization, among others.
Included in those 15,000 participants were also infections via the highly transmissible UK variant of the virus. The vaccine still posted an impressive 86.3% efficacy against the variant, which comes to an overall vaccine efficacy of 89.7% among the 15,000 participant study. Additionally, of non-placebo participants in the trial, only one case of Covid-19 was reported among those 65 and older, a demographic heavily hit by the pandemic.
原来的题头是：“各类疫苗的抗体滴度与中和性抗体滴度（摘要和解读）”，不大吸晴，只有不到700点阅。
下面链接中的文章，详细介绍了疫苗效价的评估和检测方法。
https://www.sohu.com/a/429128657_682259
上表来自于上面链接。
列举四大类疫苗的特点和抗体滴度。
倒数第二行是中和抗体滴度与恢复者血清相比较的倍数，反应了疫苗理论上的有效性。
解读如下：
1. Moderna(mRNA疫苗）在第二针后二周时的中和效价是恢复者血清的四倍左右。按年龄段，56-70岁人群最高；71+组最低。（大多数文学城网友应该在最佳年龄段，一定要去打mRNA疫苗啊）
2. Novavax（重组蛋白疫苗）与Moderna疫苗的效价接近。测试组年龄在18-59岁，没有60+。（这个疫苗也很好啊）
3. 科兴（CoronaVac)灭活疫苗的中和抗体，仅为恢复者的0.17倍（约1/6）。年龄段在18-59岁。其有效性，不言而喻。
4. 康希诺（Ad5-nCov)腺病毒载体疫苗，没有使用与上述疫苗同样的指标。但用了与科兴疫苗相同的另一指标，其数值不如科兴的。还有那个阳转率，只有约一半的受试者产生了中和抗体，在55+年龄段不到1/3。（从这些数据来看，这个疫苗不适合老年人）
这些指标测试的结果，与临床试验中所展示的有效性在总体趋势上是一致的，可以排除临试及各种报道中其它人为干扰因素的影响。（即各种阴谋论和吹牛）。
附
1. 阳转率：摘自 http://news.ynet.com/2021/01/03/3079353t70.html
“中和抗体，可以通俗地理解为能够对抗病原体的抗体，是疫苗起保护作用的基础。99.52%的中和抗体阳转率意味着，在接种两针疫苗的人中，有99.52%的受试者产生了中和抗体。
但是，产生中和抗体不代表疫苗就能起到保护作用，还需要抗体达到有效的浓度等。并且，由于个体差异，以及接触的病毒量的大小，相同浓度的抗体对不同人的保护作用可能也不同。”
2. Novavax疫苗临试数据
https://www.forbes.com/sites/williamhaseltine/2021/03/16/novavax-covid-19-vaccine-performs-well-in-clinical-trials-but-variants-remain-a-threat/?sh=129929794a7f
Against the wild-type strain of the virus, the two-dose vaccine posted 96.4% efficacy. Notably, the vaccine was also 100% effective in preventing severe disease, which included symptoms like tachypnea, high resting heart rate, required ventilation, hospitalization, among others.
Included in those 15,000 participants were also infections via the highly transmissible UK variant of the virus. The vaccine still posted an impressive 86.3% efficacy against the variant, which comes to an overall vaccine efficacy of 89.7% among the 15,000 participant study. Additionally, of non-placebo participants in the trial, only one case of Covid-19 was reported among those 65 and older, a demographic heavily hit by the pandemic.
前几天看到一篇类似的对比，之后就再也找不到了。
我看到的对照表里还有 Pfizer 的数据，记得也是4倍左右，但是略低于 Moderna 疫苗。
表中Novavax 14天中和抗体水平是3906，相当于恢复期患者3.97倍，而Moderna 18-55岁组同期中和抗体水平是 654，相当于恢复期患者水平4.1倍，这个倍数解释不通呀。